DGAP-Adhoc: BB Biotech AG reports results

2019. április 26., péntek, 06:30

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report

BB Biotech AG reports results

26-Apr-2019 / 06:30 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Media Release, April 26, 2019


BB Biotech AG reports results

In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of March 31, 2019.

Based on consolidated results, BB Biotech AG reports for the first quarter a profit of CHF 890 mn (profit of CHF 28 mn in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

Since beginning of the year, BB Biotech AG"s share price increased 24.2% in CHF and 25.4% in EUR.

The interim report as of March 31, 2019 will be published on April 26, 2019 at 7 am.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland

Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch



Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world"s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech"s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

26-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English

Schwertstrasse 6

8200 Schaffhausen

Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 803465

End of Announcement DGAP News Service

803465  26-Apr-2019 CET/CEST

Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum